logo
Plus   Neg
Share
Email

Roche : US To Purchase Addl Doses Of Antibody Cocktail For Use In Non-hospitalised COVID-19 Patients

Roche (RHHBY) confirmed that the US government will purchase additional supply of Regeneron's casirivimab and imdevimab antibody cocktail for use in non-hospitalised COVID-19 patients as part of Operation Warp Speed.

As per the new agreement, the U.S. will purchase up to 1.25 million finished doses of casirivimab and imdevimab by 30 June 2021. Regeneron is already supplying doses to treat about 300,000 people, bringing the total potential purchase to over 1.5 million doses in the US.

The US government will provide these additional doses at no cost to patients, though healthcare facilities may charge fees related to administration, and will continue to coordinate allocation of the antibody cocktail to state and territorial health departments, Roche quoted the US as saying.

Casirivimab and imdevimab were granted U.S. FDA Emergency Use Authorization for recently-diagnosed, high-risk, mild to moderate COVID-19 patients.

Roche and Regeneron are collaborating on developing and manufacturing casirivimab and imdevimab. Regeneron is distributing the antibody cocktail in the US and Roche will be responsible for distribution outside the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
Follow RTT